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Background: S-nitrosoglutathione (GSNO) serves as a reservoir for nitric oxide (NO) and thus is a key homeostatic
regulator of airway smooth muscle tone and inflammation. Decreased levels of GSNO in the lungs of asthmatics
have been attributed to increased GSNO catabolism via GSNO reductase (GSNOR) leading to loss of GSNO- and
NO- mediated bronchodilatory and anti-inflammatory actions. GSNOR inhibition with the novel small molecule,
N6022, was explored as a therapeutic approach in an experimental model of asthma.
Methods: Female BALB/c mice were sensitized and subsequently challenged with ovalbumin (OVA). Efficacy was
determined by measuring both airway hyper-responsiveness (AHR) upon methacholine (MCh) challenge using
whole body plethysmography and pulmonary eosinophilia by quantifying the numbers of these cells in the
bronchoalveolar lavage fluid (BALF). Several other potential biomarkers of GSNOR inhibition were measured
including levels of nitrite, cyclic guanosine monophosphate (cGMP), and inflammatory cytokines, as well as DNA
binding activity of nuclear factor kappa B (NFκB). The dose response, onset of action, and duration of action of a
single intravenous dose of N6022 given from 30 min to 48 h prior to MCh challenge were determined and
compared to effects in mice not sensitized to OVA. The direct effect of N6022 on airway smooth muscle tone also
was assessed in isolated rat tracheal rings.
Results: N6022 attenuated AHR (ED50 of 0.015 ± 0.002 mg/kg; Mean ± SEM) and eosinophilia. Effects were observed
from 30 min to 48 h after treatment and were comparable to those achieved with three inhaled doses of
ipratropium plus albuterol used as the positive control. N6022 increased BALF nitrite and plasma cGMP, while
restoring BALF and plasma inflammatory markers toward baseline values. N6022 treatment also attenuated the
OVA-induced increase in NFκB activation. In rat tracheal rings, N6022 decreased contractile responses to MCh.
Conclusions: The significant bronchodilatory and anti-inflammatory actions of N6022 in the airways are consistent
with restoration of GSNO levels through GSNOR inhibition. GSNOR inhibition may offer a therapeutic approach for
the treatment of asthma and other inflammatory lung diseases. N6022 is currently being evaluated in clinical trials
for the treatment of inflammatory lung disease.
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S-nitrosoglutathione (GSNO) is formed through the reac-
tion of glutathione with reactive nitrogen species and
serves as the main reservoir of cellular S-nitrosothiol
(SNO) species that govern total and/or local nitric oxide
(NO) bioavailability in vivo [1,2]. GSNO and SNOs serve
as functional depots for NO [2,3] which has a short
biological half-life [4]. Increases in bio-available NO are
associated with anti-inflammatory and smooth muscle
relaxant effects, especially in organ systems characterized
by smooth muscle and endothelial/epithelial layers such
as the respiratory, cardiovascular, and gastrointestinal
systems [5,6]. In particular, NO and GSNO help to main-
tain normal lung physiology and function via the actions
of these mediators on bronchial smooth muscle tone and
responsivity, adrenergic receptor function, and anti-
inflammatory activities [7-9].
GSNO is catabolized by S-nitrosoglutathione reductase
(GSNOR), a class III alcohol dehydrogenase (ADH) [10,11].
Therefore, GSNOR has an important role in regulating
intracellular SNOs and, subsequently, the function of these
compounds [11], while dysregulation of this enzyme can
lead to deleterious effects as observed in respiratory and
other diseases [12,13]. Specifically, there are lowered SNO
concentrations in the lungs of asthmatic patients which
have been attributed to up-regulated GSNOR activity
[13,14]. Furthermore, various alleles of the human GSNOR
gene have been associated with an increased risk of child-
hood asthma and with a decreased response to albuterol
among different ethnic populations [15-17]. The increased
GSNOR activity with subsequent loss of GSNO, SNOs,
and their associated activities, points to this enzyme as a
potential therapeutic target especially in the treatment of
respiratory diseases including asthma.
In fact, there is both preclinical and clinical evidence
supporting a role for inhibiting GSNOR in the treatment
of asthma. Que et al. (2005) showed that mice with ge-
netic deletion of GSNOR were protected from metha-
choline (MCh)-induced airway hyper-responsiveness (AHR)
following ovalbumin (OVA) sensitization and challenge
[18]. SNOs were found to be lowered in tracheal irrigations
in asthmatic children with respiratory failure in comparison
to normal children undergoing elective surgery [14]. SNO
content was decreased in the bronchoalveolar lavage fluid
(BALF) in adult patients with mild asthma compared to
healthy control subjects, and was inversely correlated
with GSNOR expression in BALF cell lysates [13]. Fur-
thermore, GSNOR activity in BALF cell lysates was sig-
nificantly increased in asthmatics compared to controls
and correlated with increased MCh responsivity [13].
Exhaled NO is increased in patients with severe asthma
[19,20] and the lowering of this parameter is used as a mea-
sure of the anti-inflammatory effectiveness of therapeutics
[21]. The increased NO in asthma has been attributed togeneration from inducible nitric oxide synthase (iNOS) in
response to inflammatory signals typical in this disease, and
NO generated in this manner can have pro-inflammatory
activity [20]. Inhibitors of iNOS have been developed for the
treatment of respiratory diseases, including asthma, in at-
tempts to mitigate the NO mediated inflammatory signals
[22,23]. Conversely, NO donors have also been developed
for the treatment of respiratory diseases for their broncho-
dilatory and anti-inflammatory benefits [24,25]. These con-
tradictions surrounding NO may be attributable to the
source (i.e., NOS isoform), amount, and location of NO
production as well as pathways involved in NO processing,
signaling, or metabolism [19,26].
As evident in asthma, increased GSNOR activity leads to
lowered GSNO and SNOs [13] in spite of the increased
NO. Similar conditions with increased NO and inflam-
mation, but potentially lowered SNOs and decreased
SNO-mediated function, are evident in non-respiratory
diseases, including cardiovascular disease [27,28] and
inflammatory bowel disease [29], in which a role for
GSNOR may exist [27,30]. GSNOR dysregulation may
therefore help explain the decreased pool of bioavailable
NO in disease states in the presence of a pro-inflammatory
NO signal.
This study evaluated the potential of GSNOR inhibition
as a therapeutic approach in the treatment of asthma.
Specifically, the effects of N6022, a novel, potent, and
selective small molecule inhibitor of GSNOR [31,32], were
evaluated in a murine model of asthma induced by sys-
temic sensitization followed by airway challenges with
OVA. Endpoints measured were AHR in response to aero-
sol challenge with MCh using non-invasive plethysmogra-
phy [33] as well as eosinophilic infiltration into the BALF.
Other determinations included assessments of nitrite,
cyclic guanosine monophosphate (cGMP), and biomarker
profiles in plasma and BALF, nuclear factor kappa B
(NFκB) activity in the lung, and modulation of airway
smooth muscle tone in a tracheal ring bioassay. These
studies showed that inhibition of GSNOR activity with a
single intravenous (i.v.) dose of N6022 imparted potent ef-
fects against key parameters in asthma, specifically, AHR
and eosinophilic inflammation, with mechanisms consis-
tent with restoring normal levels and function of SNOs in
the airways. N6022 is currently being evaluated for safety
and efficacy in clinical trials based on these findings and
the role of GSNOR in disease.Methods
Drug information
N6022, 3-(5-(4-(1H-imidazol-1-yl) phenyl)-1-(4-carbamoyl-
2-methylphenyl)-1H-pyrrol-2-yl) propanoic acid, was syn-
thesized at N30 Pharmaceuticals, Inc. [32]. N6022 has been
shown to be a potent, selective, and reversible inhibitor for
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well tolerated in animals [34].Animals
The mouse OVA study protocol was approved by the In-
stitutional Animal Care and Use Committee and attend-
ing veterinarian at BioTox Sciences, Inc. (San Diego,
CA) following guidelines provided and required under
the United States Department of Agriculture (USDA)
Animal Welfare Act (AWA) and with approval from the
Office of Laboratory Animal Welfare (OLAW). Female
BALB/c mice, 6 to 9 weeks of age at study initiation,
were obtained from Harlan (Indianapolis, IN) and
housed at BioTox Sciences. The in-life portion of the
OVA studies were performed at BioTox Sciences with
additional analyses conducted on study samples at N30
Pharmaceuticals, Inc. (Boulder, CO).
The rat tracheal ring protocol was approved by the
IACUC and attending veterinarian at Bolder BioPATH,
Inc. (Boulder, CO) following the USDA-AWA and
OLAW guidelines and approval. For tracheal ring bio-
assays, male Sprague Dawley rats that were 8 to 10
weeks of age and weighing 250 to 300 g were obtained
from Harlan (Indianapolis, IN) and housed at Bolder
BioPATH. Tissues were harvested at Bolder BioPATH
with additional processing and bioassay conducted at
N30 Pharmaceuticals.Drug administration
N6022 was reconstituted in Ca2+- and Mg2+-free phos-
phate buffered saline (PBS), pH 7.4, and administered to
mice as a single i.v. dose. In the dose response studies,
N6022 doses ranging from 0.001 mg/kg to 30 mg/kg
were given 24 h prior to the MCh challenge. PBS vehicle
was used as a control and was given as a single i.v.
administration 24 h prior to MCh. In the time course
studies, N6022 was administered i.v. at 0.1 mg/kg or
10 mg/kg from 1 h to 48 h or from 30 min to 8 h prior
to the MCh challenge. PBS vehicle was administered at
either 24 h or 8 h in these studies. A combination of
ipratropium bromide and albuterol sulfate (IpBr + Alb.;
Combivent®, Boehringer) was used as the positive con-
trol for all studies. IpBr + Alb was delivered to the lung
via inhalation (IH) as three doses, one dose each at 48 h,
24 h, and 1 h prior to MCh challenge. Each dose deliv-
ered 0.02 mg (0.9 mg/kg) IpBr and 0.1 mg (5.2 mg/kg)
Alb for a total dose of 2.7 mg/kg IpBr and 15.6 mg/kg
Alb. Administration of N6022, IpBr + Alb, and PBS at
24 h prior to MCh challenge occurred on the same day
as the last OVA airway challenge which was given on
study day 22 (see below). In these instances, compounds
were administered one hour prior to OVA.OVA sensitization
OVA was dissolved in PBS at 0.5 mg/mL and aluminum
potassium sulfate (alum) was prepared at 10% (w/v) in dis-
tilled water. Equal volumes of both solutions were mixed
together, the pH was adjusted to 6.5 using 10 N NaOH,
and the mixture was incubated for 60 min at room
temperature. This mixture was centrifuged at 750 × g for
5 min and the OVA/alum pellet was resuspended in dis-
tilled water. Mice received an intraperitoneal (i.p.) injection
of 100 μg OVA complexed with 20 mg alum in a volume of
0.2 mL on study day 1. For OVA airway challenges, mice
were anesthetized with an i.p. injection of 0.44 mg/kg keta-
mine and 6.3 mg/kg xylazine in 0.2 mL volume and placed
on a board in the supine position. OVA solution was ap-
plied intra-tracheally on days 9, 16, 19, and 22. Mice re-
ceived 250 μg OVA in 0.1 mL on day 9, and 125 μg
OVA in 0.05 mL on days 16, 19, and 22.
AHR measurement
In vivo airway responsiveness to MCh was measured in
conscious, unrestrained, spontaneously breathing mice
with whole body plethysmography using a Buxco cham-
ber (Wilmington, NC). Baseline measurements were ob-
tained, and mice were then challenged with aerosolized
saline, followed by increasing doses of MCh (5, 20, and
50 mg/mL) generated by an ultrasonic nebulizer. MCh
exposure times were five min with a one min recovery
between subsequent doses. The degree of AHR was
expressed as enhanced pause (Penh) which correlates
with the measurement of airway resistance, impedance,
and intrapleural pressure. Penh readings were averaged
over 4 min after each nebulization challenge. Penh was
calculated as follows: Penh = [(Te/Tr – 1) × (PEF/PIF)],
where Te was expiration time, Tr was relaxation time,
PEF was peak expiratory flow, and PIF was peak inspira-
tory flow × 0.67 coefficient. The time for the box pres-
sure to change from a maximum to a user-defined
percentage of the maximum represented the relaxation
time. The Tr measurement began at the maximum box
pressure and ended at 40%.
Pulmonary inflammation
After measurement of AHR, the mice were euthanized
and BALF was collected from the right lung after tying
off the left lung at the mainstem bronchus. The right
lung was lavaged three times with 0.4 mL PBS per
wash. In some studies, BALF was collected from both
lungs by lavaging four times with 1 mL PBS per wash.
Total BALF cell numbers were counted with a hema-
cytometer, the fluid was centrifuged at 200 × g for
10 min at 4°C, and a Cytospin slide of resuspended
cells was prepared. Eosinophils were quantified via
light microscopy using Diff-Quik stain (Dade Behring)
and morphological criteria. Eosinophil percent was
Blonder et al. BMC Pulmonary Medicine 2014, 14:3 Page 4 of 15
http://www.biomedcentral.com/1471-2466/14/3expressed as percent of total BALF cells and as
percent relative to the vehicle control in each study.
Tissue collection
Blood was collected into K2EDTA tubes and plasma was
obtained via centrifugation. Plasma, lungs, and BALF
supernatant (above) were snap frozen in liquid nitrogen
and stored at −80°C until analyzed.
Biomarker profiles in BALF and plasma
Inflammatory biomarker patterns in BALF and plasma were
assessed in a multi-analyte panel via immunoassay (Rodent
MAP®v2.0, Myriad-RBM, Austin, TX). Additional plasma
biomarkers included measurement of matrix metallopro-
teinase 9 (MMP-9) using the Quantikine® Mouse MMP-9
(total) Immunoassay (R&D Systems, Minneapolis, MN),
RANTES (regulated upon activation normal T-cell
expressed and secreted) using the Quantikine® Mouse
RANTES Immunoassay (R&D Systems), and cGMP using
the colorimetric Enzyme Immunoassay Direct cGMP kit
(Sigma). MMP-9, RANTES, and cGMP assays were per-
formed according to instructions provided by the manufac-
turer with detection using a SpectraMax M2 plate reader
(Molecular Devices, Sunnyvale, CA).
NFκB functional assay
All supplies were obtained from Thermo Scientific (Rock-
ford, IL). Nuclear proteins were extracted from lung
homogenates using NE-PER Nuclear and Cytoplasmic
Extraction reagents following the supplied procedures.
Protein concentration in the nuclear fractions was
determined via the bicinchoninic acid method. The bind-
ing of the NFκB p65 subunit to NFκB consensus sequence
DNA was assessed as an index of NFκB function using
the NFκB p65 Transcription Factor Assay Kit and the
supplied procedures.
Nitrite determinations
BALF nitrite was measured using ozone chemilumines-
cence detection (Sievers Nitric Oxide Analyzer, Boulder,
CO) following tri-iodide reduction of nitrite to nitric
oxide [35].
Tracheal ring bioassay
Tracheal rings containing 3 to 4 cartilage rings were
mounted at isometric tension in a small vessel wire myo-
graph (DMT 610 M, DMT-USA, Atlanta, GA) in Krebs
bicarbonate buffer containing 119 mM NaCl, 4.7 mM
KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2,
25 mM NaHCO3, 0.03 mM EDTA, and 5.5 mM glucose
and continuously gassed with 95% O2: 5% CO2. Tracheal
rings were equilibrated at a resting tension of 1 g for
one hour and then treated with 100 μM N6022, 100 μM
albuterol, or PBS vehicle for 30 min. MCh was added incumulative doses ranging from 0.01 μM to 100 μM to
induce smooth muscle contraction. In other assays,
tracheal rings were contracted with 1 μM MCh (effective
concentration 40%, EC40) and then treated with 0.3 to
100 μM N6022 or GSNO to induce relaxation. Control
rings were treated with equivalent volumes of PBS
vehicle. Data were acquired and analyzed using Powerlab
(ADInstruments, Colorado Springs, CO). Additional
data analyses were performed in GraphPad Prism 5.0
(La Jolla, CA). The amount of contraction was reported
as the percent of maximum contraction achieved in
vehicle control. The amount of relaxation was reported
as the percent of possible maximum relaxation achiev-
able per ring, i.e., peak MCh response minus the resting
tension.Statistical analyses
All data are presented as means ± SEM. Statistical analyses
for Penh, eosinophils, and biomarkers were performed
using a One-way ANOVA followed by Dunnett’s post-hoc
test or a two-tailed Student’s t-test using JMP 8.0 software
(SAS Institute, Cary, NC). Statistical analyses for the
tracheal ring bioassay were performed using a Two-way
ANOVA with treatment and dose as variables, followed by
Bonferroni’s post-hoc test (GraphPad Prism). Differences
between treatment and control groups were considered sig-
nificant at p < 0.05. The dose of N6022 that decreased Penh
by 50% (ED50) was calculated at 5, 20, and 50 mg/mL
MCh using GraphPad Prism.Results
N6022 dose response studies
The GSNOR inhibitor, N6022, demonstrated potent
effects in a mouse model of OVA-induced asthma.
When administered as a single i.v. dose at 24 h prior to
MCh challenge, N6022 caused a significant and dose-
dependent attenuation of Penh upon challenge of mice
with increasing doses of MCh aerosol (Figure 1A).
Significant attenuation of the MCh induced increases in
Penh was evident at doses of N6022 ranging from
0.01 mg/kg to 30 mg/kg when compared to vehicle
treated mice. N6022 at doses ≥ 0.005 mg/kg also caused
a significant lowering of Penh values measured at base-
line and upon exposure to saline aerosol compared to
vehicle treated mice (Figure 1A). The ED50 for N6022
from these studies was determined to be 0.015 ±
0.002 mg/kg.
N6022 also decreased the percent of BALF eosinophils
(Figure 1B), which were significantly elevated in the
OVA model as expected (Figure 1C). Significant lowe-
ring of eosinophils was achieved at all doses (0.001 to
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Figure 1 (See legend on next page.)
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Figure 1 N6022 caused a dose-dependent decrease in Penh and BALF eosinophils in OVA-sensitized and non-sensitized mice.
Non-sensitized or OVA-sensitized mice were treated with N6022 or PBS vehicle given via a single i.v. dose at 24 h prior to MCh challenge. IpBr
(0.9 mg/kg/dose) + Alb (5.2 mg/kg/dose) was administered as inhaled doses at 48 h, 24 h, and 1 h prior to MCh as a positive control for the
model. Dosing at 24 h prior to MCh challenge occurred one hour prior to the last OVA challenge on study day 22. Penh was measured at
baseline and after challenge with saline followed by increasing doses of MCh aerosol. BALF eosinophils were quantified via light microscopy.
N6022 attenuated Penh (A) and BALF eosinophils (B) in OVA-sensitized mice. OVA sensitization significantly increased BALF eosinophils (C) and
Penh (D vs. A, Vehicle). N6022 attenuated Penh in non-sensitized mice (D). Bars are the means ± SEM of 10 to 30 mice per group for (A), (B), and
(C) and 10 mice per group for (D). *p < 0.05 for treatment vs. vehicle, One-way ANOVA, Dunnett’s for (A), (B), and (D). *p < 0.05 for OVA-
sensitized vs. non-sensitized, two-tailed Student’s t-test for (C).
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N6022 in the OVA mice were evident after administra-
tion of a single i.v. dose given after three of the four air-
way challenges with OVA, and 24 h prior to the MCh
challenge. In addition, the effects of N6022 were similar
to those observed for the positive control utilized for
this model, a combination of IpBr + albuterol, which was
administered as three inhaled doses prior to the MCh
challenge (Figures 1A and 1B).
The action of N6022 was tested in mice that were not
sensitized to OVA in order to determine the ability of
this compound to directly influence airway smooth
muscle tone in the absence of ongoing inflammatory
processes. N6022 significantly attenuated the increase in
Penh upon exposure to all doses of MCh aerosol when
administered as a single 1 mg/kg i.v. dose which was the
highest dose tested in this study (Figure 1D). As
observed in the OVA model, this effect of N6022 was
similar to the effect of three inhaled doses of IpBr + Alb.Biomarker profiles
When biomarker patterns were profiled in BALF collected
from the OVA dose response studies, several biomarkers
associated with asthma and inflammation were signifi-
cantly elevated upon OVA exposure (Table 1). In particu-
lar, eotaxin, several interleukins (IL) including IL-4 and
IL-5, inflammatory cell chemoattractants including kera-
tinocyte chemoattractant/growth related oncogene alpha
(KC/GROα), macrophage inflammatory proteins (MIPs),
monocyte chemotactic proteins (MCPs), and RANTES,
and other mediators released from inflammatory cell infil-
trates including MMP-9, myeloperoxidase (MPO), and
tumor necrosis factor alpha (TNFα) were either signifi-
cantly increased or achieved detectable levels in OVA-
sensitized mice compared to non-sensitized mice (Table 1).
When mice were treated with a single dose of N6022 at
24 h prior to the MCh challenge, BALF biomarkers
were restored toward the levels in the non-sensitized
mice (Table 1). For most of these biomarkers, signifi-
cant efficacy was observed at the lowest N6022 dose of
0.1 mg/kg that was assessed within the panel, while nofurther benefit was apparent with the higher dose of
1 mg/kg N6022 (Table 1).
Biomarker patterns also were evaluated in plasma to de-
termine systemic effects in the model. Although there were
substantially fewer systemic biomarkers affected in com-
parison to BALF, significant changes in asthma-specific bio-
markers were noted (Table 2). These changes included
significant elevations in fibrinogen, haptoglobin, and inter-
leukins and a significant lowering of immunoglobulin A
(IgA) in the plasma from OVA-sensitized mice compared
to non-sensitized mice (Table 2). As observed in the BALF,
treatment with N6022 significantly restored levels of these
plasma markers toward baseline values although there
appeared to be slightly greater efficacy achieved with the
higher dose of 1 mg/kg N6022 (Table 2).NFκB activity in the lung
The effect of N6022 treatment on NFκB function was
determined due to the important role of this transcrip-
tion factor as an upstream regulator for inflammation
and tissue repair events associated with asthma [36].
In addition, NO has been shown to modulate NFκB
function and activity [37,38]. In vivo administration of
N6022 in the OVA mouse model led to a significant de-
crease in active, nuclear NFκB p65 subunit within
mouse lung tissue when compared to vehicle (Figure 2).
Thus, GSNOR inhibition by N6022 results in the down-
regulation of NFκB activation in vivo.NO and inflammatory dependent mechanisms
The ability of GSNOR inhibition to modulate NO levels
and function was determined by measuring BALF nitrite
and plasma cGMP in samples from the N6022 mouse
OVA studies. Nitrite was measured as one of the stable
end products of NO [39], while cGMP was utilized as a
marker of NO mediated activity on smooth muscle re-
laxation [36]. N6022 caused a dose-dependent increase
in nitrite, with significant elevation compared to vehicle
control at N6022 doses ≥ 10 mg/kg (Figure 3). At N6022
doses < 1 mg/kg, nitrite levels were not increased over
vehicle control (data not shown). BALF nitrate levels in
Table 1 Biomarker patterns in BALF
Biomarker1 Non-sensitized OVA-sensitized N6022 0.1 mg/kg N6022 1 mg/kg
Eotaxin 2.0 ± 0.5* 35.7 ± 13.8 3.8 ± 0.7* 7.3 ± 1.8*
Fibrinogen 2798.0 ± 697.7 52020.0 ± 15925.8 3820.0 ± 453.2* 7120.0 ± 1338.4*
FGF-9 606.0 ± 64.0* 1022.0 ± 160.7 566.0 ± 39.2* 598.0 ± 40.8*
FGF-2 1830.0 ± 311.3* 4540.0 ± 429.7 2560.0 ± 485.4* 3000.0 ± 320.9*
KC/GROα ND2 29.8 ± 8.7 ND ND
IFNγ 2.3 ± 0.3* 10.3 ± 2.5 3.6 ± 0.8* 5.3 ± 0.6*
IP-10 2.5 ± 0.2* 15.5 ± 5.3 3.5 ± 0.4* 3.7 ± 0.4*
IL-1β ND 536.0 ± 36.0 ND ND
IL-4 8.4 ± 1.1* 42.8 ± 10.2 10.7 ± 1.0* 14.4 ± 1.6*
IL-5 ND 488.2 ± 179.7 ND ND
IL-6 ND 76.3 ± 32.7 ND ND
IL-7 27.8 ± 2.9* 74.6 ± 14.9 22.2 ± 3.0* 33.4 ± 1.7*
IL-10 65.6 ± 3.1* 110.6 ± 16.7 60.4 ± 8.2* 87.2 ± 8.3
IL-11 20.6 ± 0.7* 38.0 ± 9.1 19.0 ± 1.1* 20.2 ± 1.0*
IL-12p70 22.2 ± 3.5* 48.4 ± 8.2 23.6 ± 3.9* 32.4 ± 5.2
IL-17A 1.1 ± 0.1* 2.4 ± 0.4 1.6 ± 0.3 1.7 ± 0.2
IL-18 642.2 ± 72.0* 7180.0 ± 1438.2 1252.0 ± 221.1* 1152.2 ± 220.1*
Lymphotactin 7.1 ± 1.1* 21.4 ± 4.2 10.7 ± 1.2* 11.0 ± 1.3*
MDC 11.6 ± 1.9* 203.0 ± 68.5 24.2 ± 5.6* 22.2 ± 4.2*
MIP-1α ND 1798.0 ± 321.1 404.0 ± 72.8* 378.0 ± 55.2*
MIP-1β 31.8 ± 2.7* 838.4 ± 158.9 36.6 ± 3.2* 49.4 ± 3.6*
MIP-1γ 109.2 ± 27.6* 2024.0 ± 625.3 250.0 ± 46.3* 182.0 ± 32.9*
MIP-2 4.3 ± 0.8* 39.8 ± 6.5 5.2 ± 0.8* 7.4 ± 1.5*
MIP-3β 55.2 ± 12.2* 315.4 ± 69.1 113.4 ± 21.7* 129.2 ± 27.3*
MMP-9 180.6 ± 38.7* 27180.0 ± 11205.5 230.0 ± 24.3* 308.0 ± 60.8*
MCP-1 ND 87.2 ± 31.3 ND ND
MCP-3 1.6 ± 0.1* 142.0 ± 36.0 3.0 ± 0.6* 2.8 ± 0.5*
MCP-5 0.4 ± 0.1* 3.6 ± 0.9 0.7 ± 0.2* 0.7 ± 0.2*
MPO 1550.0 ± 284.6* 435600.0 ± 104051.2 4500.0 ± 545.0* 7580.0 ± 1211.0*
SAP 43.4 ± 1.7* 144.8 ± 35.6 49.0 ± 4.6* 52.0 ± 2.3*
SCF 77.2 ± 6.6* 288.0 ± 67.9 80.0 ± 9.4* 97.0 ± 9.3*
RANTES 0.0019 ± 0.0004* 0.0077 ± 0.0025 0.0025 ± 0.0004* 0.0027 ± 0.0003*
TIMP-1 23.6 ± 2.8* 5476.0 ± 2394.1 34.0 ± 5.2* 30.2 ± 2.4*
TNFα 11.5 ± 2.9* 42.0 ± 10.0 11.1 ± 1.3* 14.7 ± 2.1*
sVCAM-1 522.0 ± 99.1* 4328.0 ± 1669.3 898.0 ± 127.8* 736.0 ± 106.1*
BALF was collected from mice by lavaging both lungs with one mL PBS four times. Biomarker levels were determined using a multi-analyte profile of biomarker
patterns. Values are the means ± SEM (N = 5).
*p < 0.05 vs. OVA-sensitized, One-way ANOVA, Dunnett’s.
1Reported in pg/mL except for fibrinogen and SAP which are reported in ng/mL. 2ND = not detectable.
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vehicle treated OVA sensitized mice (Figure 3). BALF ni-
trate levels also were determined and were found not to
differ among test groups (data not shown). Low molecu-
lar weight SNO levels in BALF were below the limits of
detection (data not shown). N6022 treatment increased
plasma cGMP, with significant elevations over vehiclecontrol when dosed from 24 h to 48 h prior to the MCh
challenge (Figure 4).
Direct actions on airway smooth muscle tone
The ability of N6022 to directly affect smooth muscle
tone in the airways was determined using tracheal ring
assays. In rat tracheal rings, pretreatment of the rings
Table 2 Biomarker patterns in plasma
Biomarker Non-sensitized OVA-sensitized N6022 0.1 mg/kg N6022 1 mg/kg
Fibrinogen 74540.0 ± 5605.7* 126250.0 ± 11070.8 32240.0 ± 7486.6* 68560.0 ± 4251.7*
Haptoglobin 22.0 ±4.3* 103.8 ±11.6* 43.4 ±13.8* 33.8 ±8.4*
IgA 366.2 ± 14.6* 236.8 ±10.0 347.2 ±14.8* 344.2 ±11.3*
IL-5 1.1 ±0.1* 2.3 ±0.3* 1.2 ±0.2* 1.0 ± 0.1*
IL-18 45.4 ±1.6* 63.0 ±2.1 51.4 ±6.5 50.6 ±2.4*
Plasma biomarker levels were determined using a multi-analyte profile of biomarker patterns. Values are the means ± SEM (N = 5) in either μg/mL (Fibrinogen,
Haptoglobin, and IgA) or ng/mL (IL-5 and IL-18).
*p < 0.05 vs. OVA-sensitized, One-way ANOVA, Dunnett’s.
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http://www.biomedcentral.com/1471-2466/14/3with 100 μM N6022 for 30 min caused a significant at-
tenuation of airway smooth muscle contraction induced
by cumulative doses of MCh (Figure 5). Significant effects
of N6022 were evident at MCh doses ≥ 5 μM when com-
pared to PBS vehicle treated rings. Albuterol was tested as
a control and also showed the expected attenuation of
tracheal smooth muscle contraction induced by MCh
under the same experimental conditions (Figure 5A).
The ability of N6022 to relax tracheal rings following
MCh contraction also was determined. In these tests,
N6022 demonstrated a dose-dependent relaxation with
significant effects at 100 μM compared to rings treated
with equivalent volumes of PBS vehicle (Figure 5B).
GSNO was tested as a control and showed a dose-
dependent relaxation with significant effects at GSNO
doses ≥ 3 μM compared to rings treated with equivalent






























Figure 2 N6022 decreased NFκB activity in the lungs.
OVA-sensitized mice were treated with a single i.v. dose of either
N6022 or PBS vehicle administered 24 h prior to MCh challenge
which was one hour prior to the last OVA airway challenge. Nuclear
proteins were extracted from lung homogenates and tested for their
ability to bind to the DNA consensus sequence for NFκB DNA via
immunoassay as a measure of NFκB function. Bars are the means ±
SEM of 5 mice per group. *p < 0.05 for N6022 vs. vehicle, two-tailed
Student’s t-test.N6022 onset and duration of action
Studies assessing the time course of N6022 effect in the
mouse OVA model were performed to explore the onset
and duration of action of this compound (Figures 6 and
7). Administration of a single i.v. dose of 0.1 mg/
kg N6022 at 1 h to 48 h prior to MCh challenge caused
significant decreases in Penh upon MCh exposure at all
time points assessed in this study in comparison to
vehicle treated mice (Figure 6A). N6022 also significantly
decreased BALF eosinophils at all time points in com-
parison to vehicle treated mice (Figure 6B). There
appeared to be a time-dependent influence of N6022
on both Penh and eosinophilia, with greater efficacy
observed from 12 h to 48 h. The actions of N6022 were
comparable to those observed for the positive control
(three IH doses of IpBr + Alb) which caused significant
decreases in Penh at 5, 20, and 50 mg/mL MCh
challenges (Figure 6A) and a significant lowering of
eosinophils (Figure 6B).
In a second time course study, the effect of N6022
administered at 30 min to 8 h prior to MCh challenge
was assessed to more fully explore the onset of action.
N6022 caused significant decreases in Penh at 50 mg/
mL MCh challenge when dosed at 10 mg/kg i.v. at
30 min to 4 h prior to MCh challenge in comparison to
vehicle treated mice (Figure 7A). When given at 8 h
prior to MCh challenge, N6022 caused significant
decreases in Penh at all doses of MCh challenge
(Figure 7A). In this study, N6022 also significantly lo-
wered the number of eosinophils compared to vehicle
(Figure 7B). As observed above in the onset and dur-
ation of action study, the effects of N6022 were
dependent on time of N6022 dosing prior to the MCh
challenge, with greater benefit observed at the latest
time point (8 h) assessed. The three IH doses of the
positive control, IpBr + Alb, showed the expected signifi-
cant effects on Penh and BALF eosinophils (Figures 7A
and 7B).
Two biomarkers involved in inflammatory and tissue
repair events in asthma were measured in these time
course studies to further explore the time-dependent


















Figure 3 N6022 increased BALF nitrite. OVA-sensitized mice were treated with a single i.v. dose of either N6022 or PBS vehicle administered
24 h prior to MCh challenge which was one hour prior to the last OVA airway challenge. Non-sensitized mice treated with a single i.v. dose of
PBS at 24 h prior to MCh challenge (one hour prior to OVA) also were assessed. Nitrite levels in BALF were measured via ozone
chemiluminescence. Bars are the means ± SEM of 6 mice per group. *p < 0.05 for N6022 vs. vehicle, One-way ANOVA, Dunnett’s.
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http://www.biomedcentral.com/1471-2466/14/3asthma model. As shown in Figure 6C, N6022 signifi-
cantly decreased plasma levels of MMP-9, an inflamma-
tory biomarker and chemokine involved in tissue
turnover and repair [40]. N6022 treatment lowered
MMP-9 compared to vehicle controls starting after 12 h,
with significant and similar actions achieved when
administered from 24 h to 48 h prior to MCh challenge
(Figure 6C). N6022 also attenuated plasma levels of
RANTES (Figure 7C), a cytokine responsible for eosino-
phil recruitment [41]. N6022 treatment lowered plasma
RANTES compared to vehicle controls when adminis-
tered from 1 h to 4 h prior to MCh, with significant and
maximal action achieved when administered at 8 h prior
to MCh in this study (Figure 7C). Treatment of mice
with three inhaled doses of IpBr + albuterol did not
















Figure 4 N6022 treatment increased plasma cGMP. OVA-sensitized mic
24 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 24
occurred one hour prior to the last OVA challenge on study day 22. Plasma
SEM of 5 mice per group. *p < 0.05 for treatment vs. vehicle, One-way ANODiscussion
Results of these studies show that N6022, a potent and
selective inhibitor of GSNOR activity, has significant
bronchodilatory and anti-inflammatory effects in a
mouse model of allergic asthma. The effects of N6022
occurred as early as 30 min post-administration, were
greater at 12 h and later after administration, and were
sustained for at least 48 h after administration. Efficacy
with N6022 was achieved with a single i.v. dose and was
comparable to that observed after administration of
three inhaled doses of the anti-cholinergic, ipratropium
bromide, combined with the β2 agonist, albuterol.
N6022 also lowered Penh following MCh exposure
in non-sensitized mice and decreased MCh-induced
smooth muscle contraction in the tracheal ring assays.
These findings show that GSNOR inhibition by N602224 h 36 h 48 h
*
 challenge (0.1 mg/kg N6022)
**
e were treated with a single i.v. dose of N6022 administered 1 h to
h prior to MCh challenge. Dosing at 24 h prior to MCh challenge
cGMP was assessed via enzyme immunoassay. Bars are the means ±
VA, Dunnett’s.
A B
Figure 5 N6022 attenuated MCh-induced contraction in isolated tracheal rings. Rat tracheal rings were mounted in a small vessel wire
myograph and pretreated with PBS vehicle, N6022, or albuterol for 30 min, after which cumulative doses of MCh were added to induce
contraction (A). In other tests, tracheal rings were contracted with 1 μM MCh (EC40) followed by cumulative dose additions of N6022 or GSNO to
induce relaxation (B). Values are the means ± SEM of 6 to 8 tracheal rings per treatment for (A) and 4 to 16 tracheal rings per treatment for (B).
*p < 0.05 N6022 vs. vehicle at MCh doses ≥ 5 μM and *p < 0.05 Albuterol vs. vehicle at MCh doses ≥ 1 μM, Two-way ANOVA, Bonferroni’s for (A).
*p < 0.05 N6022 vs. vehicle at N6022 doses of 100 μM and *p < 0.05 GSNO vs. vehicle at GSNO doses≥≥ 3 μM, Two-way ANOVA, Bonferroni’s
for (B).
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http://www.biomedcentral.com/1471-2466/14/3directly influences smooth muscle tone in the airways.
However, the potency of N6022 on Penh was approxi-
mately 100-fold greater in OVA-sensitized mice com-
pared to non-sensitized mice as there were significant
and similar actions at 0.01 mg/kg vs. 1 mg/kg N6022 in
OVA- vs. non-sensitized mice, respectively. This differ-
ence suggests an important contribution of anti-inflam-
matory mechanisms on mitigating AHR in response to
MCh challenge.
In fact, considerable anti-inflammatory actions of
GSNOR inhibition by N6022 were evident as noted by
significant reductions in BALF eosinophils as well as
BALF and systemic inflammatory biomarkers explored
in both the dose response and time course OVA studies.
These potent anti-inflammatory actions of N6022 may
occur in part through NFκB pathways. NFκB has an im-
portant role as an upstream regulator of inflammatory
signals, including signals in asthma and the asthma-
associated biomarkers that were measured in the current
study [37]. Additionally, NFκB is regulated in part by
nitrosation of key cysteine residues which leads to a de-
crease in NFκB function [37,38]. Our data demonstrat-
ing the ability of N6022 to decrease NFκB DNA binding
in lungs from the OVA mouse studies suggest that
GSNOR inhibition likely attenuates inflammation at
least in part by down-regulating NFκB activation. Given
that N6022 treatment also increased BALF nitrite and
plasma cGMP, endpoints used as markers of bioavailable
NO [42,43], the anti-inflammatory effects of GSNORinhibition are consistent with SNO-dependent inhibition
of NFκB-mediated signaling. Previously published stu-
dies suggest that this SNO-mediated effect may occur
through inhibition of transcription factor DNA binding
activity [44] or inhibition of pathway activation via nitro-
sation of IKKβ [45].
The difference in potency observed for N6022 in OVA-
sensitized compared to non-sensitized mice also may be
explained by differences in activities of the restored GSNO
and SNO pools and down-stream nitrosation targets. For
example, restoring the levels of GSNO/SNOs may miti-
gate against disease, whereas in non-disease states, these
levels are sufficient and no further benefit or effect is
achieved or measurable upon GSNOR inhibitor treatment.
In support of this hypothesis, treatment of rats with a
related GSNOR inhibitor decreases blood pressure and
nitric-oxide dependent flow mediated vasodilation in a
salt-induced hypertensive rat model, whereas no effect of
the GSNOR inhibitor is noted in normotensive rats [46].
The bronchodilatory capacity observed with N6022
administration is consistent with observations reported
in GSNOR knock-out mice, which showed that genetic
deletion of GSNOR protected mice from MCh-induced
bronchoconstriction compared to wild-type control mice
[18]. Similar to N6022, more pronounced effects were
evident in GSNOR knock-out mice under the conditions
of OVA-induced asthma compared to the non-sensi-
tized model. However, in contrast to the potent anti-
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Figure 6 N6022 exhibited a sustained duration of action in OVA-sensitized mice. OVA-sensitized mice were treated with a single i.v. dose
of N6022 administered 1 h to 48 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 24 h prior to MCh challenge. IpBr + Alb was
administered as inhaled doses at 48 h, 24 h, and 1 h prior to MCh as a positive control for the model. Dosing at 24 h prior to MCh challenge
occurred one hour prior to the last OVA challenge on study day 22. Penh was measured at baseline and after challenge with saline followed by
increasing doses of MCh aerosol. BALF eosinophils were quantified via light microscopy. Plasma MMP-9 was measured via ELISA. N6022
attenuated Penh (A), BALF eosinophils (B), and plasma MMP-9 (C) in OVA-sensitized mice starting as early as one hour with effects sustained for
up to 48 h. Bars are the means ± SEM of 10 mice per group for (A) and (B), and 5 mice per group for (C). *p < 0.05 for treatment vs. vehicle,
One-way ANOVA, Dunnett’s.
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http://www.biomedcentral.com/1471-2466/14/3inflammatory responses (BALF eosinophils, BALF IL-13,
and serum IgE) were not decreased in GSNOR knock-out
mice upon exposure to OVA. The reason for differences in
anti-inflammatory influences between genetic deletion and
pharmacologic inhibition is not clear, but may be due to
differences between life-long homozygous gene deletion of
GSNOR and the reversible inhibition of GSNOR activity
with a pharmacologic approach. Further contributing factors
may include differences in the experimental model such asmouse strain, asthma induction protocol, and endpoints
measured.
NO produced from iNOS, upon up-regulation of this
enzyme during inflammation, is known to be increased in
the expired breath of asthmatics [21], and plays a significant
role in the inflammatory responses observed in atopic
asthma [19,21,47]. Thus, increasing the pool of bioavailable
NO through GSNOR inhibition may appear contradictory.
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Figure 7 N6022 exerted a rapid onset of action in OVA-sensitized mice. OVA-sensitized mice were treated with a single i.v. dose of N6022
administered 30 min to 8 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 8 h prior to MCh challenge. IpBr + Alb was adminis-
tered as inhaled doses at 48 h, 24 h, and 1 h prior to MCh as a positive control for the model. Penh was measured at baseline and after challenge
with saline followed by increasing doses of MCh aerosol. BALF eosinophils were quantified via light microscopy. Plasma RANTES was measured
via enzyme immunoassay. N6022 attenuated Penh (A), BALF eosinophils (B), and plasma RANTES (C) in OVA-sensitized mice starting as early as
30 minutes with more pronounced effects occurring at 8 h. Bars are the means ± SEM of 10 mice per group for (A) and (B), and 4 mice per group
for (C). *p < 0.05 for treatment vs. vehicle, One-way ANOVA, Dunnett’s.
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http://www.biomedcentral.com/1471-2466/14/3lungs of asthmatic patients [13] even in the presence of the
increased exhaled NO [19,20,48] which may be explained by
increased GSNOR activity. These findings suggest that the
mechanisms by which SNO pools mediate bronchodilatory
and anti-inflammatory effects are distinct from the actions of
the relatively high concentrations of NO produced by iNOS.
These findings also suggest that iNOS derived NO is not ne-
cessarily responsible for SNO levels observed in the BALF.
In support of this hypothesis, GSNOR inhibitors attenuate
iNOS protein expression in cellular models of cytokine-
stimulated inflammation ([49] and SCM, GJR unpublishedresults). Our studies suggest that inhibition of GSNOR, and
the likely subsequent elevation of SNOs, result in attenuation
of proinflammatory mediators, in part via down regulation
of NFκB signaling. Inhibition of GSNOR as a mechanism to
increase SNO pools is thus plausible and of potential benefit
in asthma therapy, as noted by efficacy in the mouse model
of asthma in the current studies. These proposed mecha-
nisms are consistent with data demonstrating protection
from experimental asthma in the GSNOR knock-out mouse
[18] and the attenuation of asthma severity in an OVA
model following GSNO administration [50]. Taken together,
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activity in asthma patients may be an important component
of asthma pathophysiology as previously suggested [13,14].
The results and mechanisms noted in the current stud-
ies are consistent with other observations in inflamma-
tory disease models in which dysregulated GSNOR and/
or altered SNO homeostasis may have important roles.
In particular, the pathophysiology of diseases of the re-
spiratory [12,13,20], gastrointestinal [29,30], and cardio-
vascular [27,28] systems involve inflammatory and NO-
mediated pathways which have the potential to be regu-
lated by GSNOR. N6022 and other inhibitors of GSNOR
have been shown to decrease inflammation and disease
severity in animal models of tobacco smoke induced
chronic obstructive pulmonary disease [51], chemically
induced colitis [52], acetaminophen induced hepatoto-
xicity [53], and high salt diet induced hypertension [46].
Direct measurements of airway mechanics were not
performed in the current studies, but rather Penh was
derived via whole body plethysmography with a Buxco
chamber and used as an index of AHR. This technique
was chosen as it offers a noninvasive method to measure
lung mechanics in unanesthetized and unrestrained mice
while allowing for MCh challenge via aerosol/inhalation
exposure. While some controversy exists as to the
adequacy of Penh as a measure of AHR [54,55], Penh
has been shown to be a valid measure of AHR in aller-
gen sensitized mice and to positively correlate with a dir-
ect measure of airway resistance using mechanical
ventilation in anesthetized and surgically implemented
mice of the same strain utilized in these studies [33].
There were some questions that could not be addressed
in these studies due to analytical limitations. Although
N6022 is a potent and selective inhibitor of human GSNOR
activity in vitro [31,32], inhibition occurs via a reversible
process which precludes the direct measurement of GSNOR
inhibition in vivo since tissue processing and dilution leads
to dissociation of GSNOR inhibitors from the enzyme-
substrate complex [31]. Another limitation was the inability
to detect GSNO and SNOs in mouse lung or BALF samples.
SNOs were assessed using ozone chemiluminescence detec-
tion with a nitric oxide analyzer (Sievers) following tri-
iodide reduction after prior treatment with sulfanilamide to
remove contaminating nitrite signal [56,57]. The detec-
tion limit of this assay was 5 pmoles or 50 nM.
GSNOR inhibition in these studies may have indeed
caused increased GSNO as suggested by the effects on
endpoints influenced by GSNO including bronchodilation,
increased BALF nitrite, increased plasma cGMP, and de-
creased NFκB activity. Because GSNOR can catalyze the
reduction of certain aldehydes in addition to the oxidation
of GSNO [10,11], an alternative consideration is that the
physiological effects of GSNOR inhibition could be due to
inhibition of aldehyde reduction rather than the GSNOoxidation reaction. However, there is no evidence that the
aldehyde substrates are involved in the endpoints men-
tioned above, whereas GSNO has been shown in many
studies to influence these measurements [13,58,59].
Direct measurement of endogenous GSNO and SNOs is
challenging because levels are usually below the limits of
detection of current methods. Other investigators also
state the inability to detect GSNO in the BALF of asthma
patients [13,60]. In this example, the investigators mea-
sured high and low molecular weight (i.e., GSNO) SNOs
using photolysis-chemiluminescence in the absence or
presence of HgCl2 to cleave thiol-bound NO. The limit of
detection was 2 pmoles. Values reported for total SNOs
were 10–20 pmoles/mL (10–20 nM) which are close to
our detection limit of 50 nM. It was noted that N6022
did increase BALF nitrite which was utilized as a stable
marker of NO, although the detection of nitrite did not
correlate with N6022 efficacy at every dose. Similar dis-
parities between physiologic or pharmacologic effects
and GSNO levels have been noted in a study showing
that efficacy of GSNO was evident at lower doses than
those that caused increased BALF SNOs in experimen-
tal asthma [49].
Conclusions
GSNOR inhibition with N6022 in an experimental model
of asthma demonstrated significant efficacy toward key
parameters associated with asthma including AHR in re-
sponse to MCh challenge, pulmonary eosinophilia, and
both pulmonary and systemic inflammatory biomarkers.
GSNOR has recently emerged as a potential target in
human asthma and other inflammatory lung diseases. The
role of GSNOR in human disease, along with the current
findings with the GSNOR inhibitor, N6022, point to
GSNOR inhibition as a novel target for the treatment
of asthma and other inflammatory lung disease. This ra-
tionale has prompted the current evaluation of N6022 in
clinical trials for the treatment of inflammatory lung
disease including asthma and cystic fibrosis.
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